Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Sweet, KL; Pemmaraju, N; Lane, AA; Stein, AS; Vasu, S; Blum, W; Rizzieri, DA; Wang, ES; Rowinsky, EK; Szarek, M; Brooks, CL; Disalvatore, S; Liu, D; Duvic, M; Schwartz, JD; Konopleva, M

Published Date

  • December 3, 2015

Published In

Volume / Issue

  • 126 / 23

Published By

Pages

  • 3

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 57th Annual Meeting of the American-Society-of-Hematology

Conference Location

  • Orlando, FL

Conference Start Date

  • December 5, 2015

Conference End Date

  • December 8, 2015